Source: Eur Respir J 2015; 45: 1066-1080
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Huertas Alice, Tu Ly, Thuillet Raphaël, Le Hiress Morane, Phan Carole, Ricard Nicolas, Nadaud Sophie, Fadel Elie, Humbert Marc, Guignabert Christophe. Leptin signalling system as a target for pulmonary arterial hypertension therapy. Eur Respir J 2015; 45: 1066-1080

Member's Comments

No comment yet.

Related content which might interest you: Beyond a single pathway: combination therapy in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 408-417 Year: 2016 Dysregulation of TGF-β/BMP signaling in a monocrotaline model of pulmonary hypertension Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment? Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension Year: 2007 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 Apelin improves cardiac output in patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Impact of therapies on insulin resistance in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006 Autoimmunity and pulmonary arterial hypertension: The role of leptin Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research Source: Eur Respir J, 50 (2) 1700983; 10.1183/13993003.00983-2017 Year: 2017 Endothelial control of BMPR2 signalling in experimental shunt-induced pulmonary arterial hypertension Source: Research Seminar 2005 - Pulmonary Circulation: Molecular Determinants of Pulmonary Vascular Remodelling Year: 2005 Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension}, Source: Eur Respir J 2012; 40: 895-904 Year: 2012 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021 Targeting BMPR-II in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary arterial hypertension: future therapeutic approaches Year: 2016 Insulin resistance in pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 318-324 Year: 2009 Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1483-1485 Year: 2010 Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension Source: Eur Respir J, 53 (6) 1801524; 10.1183/13993003.01524-2018 Year: 2019 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013